Literature DB >> 19025795

Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma.

Till Milde1, Stefan Pfister, Andrey Korshunov, Hedwig E Deubzer, Ina Oehme, Aurélie Ernst, Anna Starzinski-Powitz, Angelika Seitz, Peter Lichter, Andreas von Deimling, Olaf Witt.   

Abstract

Nonresectable ependymomas are associated with poor prognosis despite intensive radiochemotherapy and radiation. The molecular pathogenesis of ependymoma initiation and progression is largely unknown. We here present a case of therapy-refractory, progressive ependymoma with cerebrospinal as well as extraneural metastases, which allowed us for the first time to follow the stepwise accumulation of chromosome aberrations during disease progression. Genome-wide DNA copy-number analysis showed sequential deletions on chromosomes 1, 9, and 14 as well as a homozygous deletion of the CDKN2A locus, underscoring its role in tumor progression. Gradual loss at 1p36 was associated with loss of protein expression of the putative tumor suppressor gene AJAP1/SHREW1. In summary, this is the first report on acquired genomic aberrations in ependymoma over time pointing to novel candidate tumor suppressor genes. This analysis provides molecular insights into the chronology of genetic events in this case from initial localized tumor to widespread metastasized disease. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19025795     DOI: 10.1002/gcc.20635

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma.

Authors:  Ningjing Lin; Chunhui Di; Kathy Bortoff; Jinrong Fu; Peter Truszkowski; Patrick Killela; Chris Duncan; Roger McLendon; Darell Bigner; Simon Gregory; David Cory Adamson
Journal:  Mol Cancer Res       Date:  2012-01-12       Impact factor: 5.852

2.  A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.

Authors:  Till Milde; Susanne Kleber; Andrey Korshunov; Hendrik Witt; Thomas Hielscher; Philipp Koch; Hans-Georg Kopp; Manfred Jugold; Hedwig E Deubzer; Ina Oehme; Marco Lodrini; Hermann-Josef Gröne; Axel Benner; Oliver Brüstle; Richard J Gilbertson; Andreas von Deimling; Andreas E Kulozik; Stefan M Pfister; Ana Martin-Villalba; Olaf Witt
Journal:  Acta Neuropathol       Date:  2011-08-24       Impact factor: 17.088

3.  MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.

Authors:  Johannes Nowak; Stephanie Theresa Jünger; Henner Huflage; Carolin Seidel; Annika Hohm; Lindsey A Vandergrift; Katja von Hoff; Stefan Rutkowski; Torsten Pietsch; Monika Warmuth-Metz
Journal:  Clin Neuroradiol       Date:  2018-07-19       Impact factor: 3.649

Review 4.  Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas.

Authors:  Isaac Yang; Daniel T Nagasawa; Won Kim; Marko Spasic; Andy Trang; Daniel C Lu; Neil A Martin
Journal:  J Clin Neurosci       Date:  2012-04-18       Impact factor: 1.961

Review 5.  A survey of metastatic central nervous system tumors to cervical lymph nodes.

Authors:  Vanni Mondin; Alfio Ferlito; Kenneth O Devaney; Julia A Woolgar; Alessandra Rinaldo
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-08       Impact factor: 2.503

Review 6.  Molecular genetics of ependymoma.

Authors:  Yuan Yao; Stephen C Mack; Michael D Taylor
Journal:  Chin J Cancer       Date:  2011-10

7.  Alternative exon usage creates novel transcript variants of tumor suppressor SHREW-1 gene with differential tissue expression profile.

Authors:  Petra A B Klemmt; Eduard Resch; Isabell Smyrek; Knut Engels; Ernst H K Stelzer; Anna Starzinski-Powitz
Journal:  Biol Open       Date:  2016-11-15       Impact factor: 2.422

8.  Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.

Authors:  Theophilos Tzaridis; Till Milde; Kristian W Pajtler; Sebastian Bender; David T W Jones; Simone Müller; Andrea Wittmann; Magdalena Schlotter; Andreas E Kulozik; Peter Lichter; V Peter Collins; Olaf Witt; Marcel Kool; Andrey Korshunov; Stefan M Pfister; Hendrik Witt
Journal:  Oncotarget       Date:  2016-09-20

9.  AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival.

Authors:  Chunhui Di; Nikol Mladkova; James Lin; Brian Fee; Miriam Rivas; Kang Chunsheng; Darell Bigner; David Cory Adamson
Journal:  Int J Oncol       Date:  2017-11-01       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.